Physician profile
Eric S Dunn
NPI 1144380452
$1,908.00
in general payments reported to CMS, 2019-2025
20 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $111 · 2021: $162 · 2022: $593 · 2023: $344 · 2024: $266 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.39 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $325.38 | 2023-2024 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $260.56 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $258.85 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $205.50 | 2023-2025 | Clareon, Hydrus Microstent, Rocklatan |
| New World Medical,INC. | $142.03 | 2022-2024 | Kahook Dual Blade, Streamline, Ahmed Glaucoma Valve |
| The Cameron-Ehlen Group, INC. | $121.93 | 2022 | |
| Abbvie INC. | $118.05 | 2022-2025 | Durysta |
| Carl Zeiss Meditec USA, INC. | $99.15 | 2021-2022 | |
| Allergan, INC. | $85.43 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $62.63 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $41.49 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.66 | 2019-2021 | |
| Amgen INC. | $29.19 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $25.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.56 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $18.48 | 2023 | Rayone Spheric, Omidria, Rayone Emv |
| Eyepoint US, INC. | $17.91 | 2019 | |
| Horizon Therapeutics Plc | $14.49 | 2023 | Tepezza |
| Avanir Pharmaceuticals, INC. | $14.04 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.